

5 March 2025

Argent BioPharma Ltd.
(Argent BioPharma or the Company)

Appointment of Non-Executive Director

Argent BioPharma, a clinical-stage biopharma company, is pleased to announce the appointment of Mr Gary Hermon as a non-executive director of the Company.

Mr Hermon is a seasoned Company Director with over 30 years of experience in telecommunications, electrical systems, and infrastructure rollout. Throughout his career, he has successfully managed projects for notable clients, including Hewlett-Packard, the Victorian Government, BP, and ExxonMobil. At Haumea Pty Ltd, Gary focuses on cable data infrastructure, CCTV systems, and communications networks, ensuring efficient and high-quality project delivery.

Previously, Mr Hermon founded Hercomm Cables & Security, where he managed nationwide rollouts for Hewlett-Packard and the Victorian Government. He also has extensive experience overseeing electrical systems and communications for BP and ExxonMobil in Indonesia, India, and Papua New Guinea. With a strong track record in project management and infrastructure delivery, Mr Hermon is known for his leadership and technical expertise across various sectors.

Mr Hermon's appointment coincides with Mr Layton Mills official resignation as a director of the Company.

Roby Zomer, Argent's CEO and Managing Director commented: *"We are delighted to welcome Gary onto the Board of Argent BioPharma. We believe his leadership will help strengthen the company's technological and operational capabilities and assist in advancing our clinical pipeline".*

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com



About Argent BioPharma

Argent BioPharma Limited (ASX: RGT; OTCQB: RGTLF) is an innovative clinical-stage biopharmaceutical company specialising in neuroimmunology, developing advanced nano-medicines to address unmet medical needs in central nervous system (CNS) disorders and immune-related conditions. By leveraging cutting-edge technologies, including the Neuro-Immune Modulatory (NIM) System and its role in coordinating nervous and immune responses, Argent BioPharma's robust pipeline—featuring lead candidates like CannEpil®, CogniCann®, and CimetrA®—targets complex diseases where effective treatments are lacking. Through a commitment to science-driven innovation and patient-centered outcomes, Argent BioPharma is reshaping the future of care for chronic, inflammatory, and neurodegenerative diseases

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma



Argent BioPharma Ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 info@argentbiopharma.com